
Sep 16, 2026
Medisights Pioneers New Standard: AI Agents Capture Unprecedented Near Real-Time Market Intelligence in Complex Diseases Like Multiple Myeloma
NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Medisights, the AI-native platform for life sciences, today announced the successful completion of a landmark study demonstrating that purpose-built Artificial Intelligence (AI) agents can seamlessly navigate the intricate, rapidly evolving landscape of Multiple Myeloma to capture actionable market intelligence at scale. By successfully training AI to track this highly complicated disease state, Medisights has pioneered a new methodology for unlocking phy




